A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of CHF6467 After Single and Repeated Ascending Doses in Subjects With Diabetic Neurophatic Foot Ulcers (DFU)
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs CHF 6467 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; First in man
- Sponsors Chiesi Farmaceutici
- 03 Feb 2021 Status changed from recruiting to completed.
- 10 Sep 2019 New trial record